Baseline characteristics of patients enrolled in this study
| Characteristic | Chemo-IM | Chemo (n=39) | |||||||
| GDPH cohort (n=60) | FPHF cohort (n=29) | ||||||||
| pCR (No, %) | non-pCR (No, %) | P value* | pCR (No, %) | non-pCR (No, %) | P value* | pCR (No, %) | non-pCR (No, %) | P value* | |
| Median age (range) | 48 (28–70) | 51 (36–66) | 0.92 | 51 (37–70) | 55 (44–62) | 0.924 | 51 (23–67) | 51 (32–69) | 0.38 |
| Menstrual status | 0.425 | 0.228 | 0.429 | ||||||
| Premenopausal | 20 (54.1) | 10 (43.5) | 9 (50.0) | 3 (72.7) | 8 (40) | 10 (52.6) | |||
| Postmenopausal | 17 (45.9) | 13 (56.5) | 9 (50.0) | 8 (27.3) | 12 (60) | 9 (47.4) | |||
| T stage† | 0.265 | 0.0547 | 0.055 | ||||||
| T1 | 5 (13.5) | 3 (13) | 6 (33.3) | 0 | 2 (10) | 1 (5.3) | |||
| T2 | 21 (56.8) | 14 (60.9) | 8 (44.5) | 9 (81.8) | 16 (80) | 13 (68.4) | |||
| T3 | 9 (24.3) | 2 (8.7) | 4 (22.2) | 1 (9.1) | 0 | 5 (26.3) | |||
| T4 | 2 (5.4) | 4 (17.4) | 0 | 1 (9.1) | 2 (10) | 0 | |||
| N stage† | 0.444 | 0.89 | 0.024 | ||||||
| N0 | 16 (43.3) | 8 (34.8) | 1 (5.6) | 1 (9.1) | 15 (75) | 6 (31.6) | |||
| N1 | 12 (32.4) | 8 (34.8) | 16 (88. 9) | 9 (81.8) | 4 (20) | 11 (57.9) | |||
| N2 | 8 (21.6) | 4 (17.4) | 0 | 0 | 1 (5) | 2 (10.5) | |||
| N3 | 1 (2.7) | 3 (13.0) | 1 (5.6) | 1 (9.1) | 0 | 0 | |||
| Overall stage† | 0.835 | 0.75 | 0.183 | ||||||
| I | 1 (2.7) | 1 (4.3) | 0 | 0 | 2 (10) | 0 | |||
| II | 22 (59.5) | 12 (52.2) | 14 (77.8) | 8 (72.7) | 16 (80) | 14 (73.7) | |||
| III | 14 (37.8) | 10 (43.5) | 4 (22.2) | 3 (27.3) | 2 (10) | 5 (26.3) | |||
| Chemo-IM regimen | 0.811 | 1.0 | 0.152 | ||||||
| Nab-pac/Carbo+anti-PD1 | 14 (37.8) | 8 (34.8) | 18 (100.0) | 11 (100.0) | / | / | |||
| EC-Nab-pac+anti-PD1 | 23 (62.2) | 15 (65.2) | 0 | 0 | / | / | |||
| Nab-pac+Carbo | / | / | 13 (65) | 8 (42.1) | |||||
| EC-Nab-pac | / | / | 7 (35) | 11 (57.9) | |||||
| Pathological grade‡ | 0.02 | 0.033 | 0.016 | ||||||
| I–II | 8 (22.2) | 11 (52.4) | 1 (5.6) | 4 (36.4) | 5 (25) | 12 (63.2) | |||
| III | 28 (77.8) | 10 (47.6) | 17 (94.4) | 7 (63.6) | 15 (75) | 7 (36.8) | |||
| Median Ki67 (range) | 75 (20–95) | 60 (10–95) | 0.018 | 60 (20–95) | 60 (20–90) | 0.876 | 73 (25–90) | 60 (8–85) | 0.04 |
*P values were calculated by the χ² test for categorical variables and student’s t-test for continuous variables.
†According to the eighth edition of the International Union against Cancer/American Joint Committee on Cancer (UICC/AJCC) staging manual.
‡Three patients in the Chemo-IM cohort did not have such data.
anti-PD-1, sintilimab, camrelizumab or pembrolizumab; Carbo, carboplatin; Chemo-IM, chemotherapy plus immunotherapy; EC, epirubicin plus cyclophosphamide; FPHF, First People’s Hospital of Foshan; GDPH, Guangdong Provincial People’s Hospital; Nab-pac, albumin-bound paclitaxel; non-pCR, non-pathological complete response; pCR, pathological complete response.